LA GESTIONE DELL’ASCITE E DELLA IPONATREMIA NEL CIRROTICO: LE NUOVE LINEE GUIDA 2025 DELL’AGA. DA “GASTROENTEROLOGY” (FREE)

EPATOLOGIA, EPATOLOGIA ONCOLOGICA, MEDICINA INTERNA, NEWSLETTER

AGA Clinical Practice Update on the Management of Ascites, Volume Overload, and Hyponatremia in Cirrhosis: Expert Review Eric S. Orman et al. Abstract Description The purpose of this American Gastroenterological Association (AGA) Institute Clinical Practice Update (CPU) is to summarize the available evidence and offer expert Best Practice Advice (BPA) on the management of ascites, hepatic…

STIPSI CRONICA DELL’ADULTO. PENSAVATE DI SAPERE TUTTO ? MEGLIO KIWI O PSYLLOGEL? SEGUITE LA NUOVE LINEE GUIDA DELLA ASSOCIAZIONE BRITANNICA DI NUTRIZIONE. DA”JHND” (FREE)

DISPEPSIA, GASTROENTEROLOGIA, IBS, MEDICI DI FAMIGLIA, MEDICINA DEI PROBIOTICI, MEDICINA INTERNA, NEWSLETTER

British Dietetic Association Guidelines for the Dietary Management of Chronic Constipation in Adults Eirini Dimidi et al. Abstract Background: Current clinical guidelines for chronic constipation offer limited dietary recommendations. The aim of this project was to develop the first comprehensive evidence-based dietary guidelines for the management of chronic constipation in adults. Methods: Four systematic reviews and meta-analyses…

COLON IRRITABILE. PENSAVATE DI SAPERE TUTTO, EH? OCCHIO ALLA NUOVA REVIEW EVIDENCE-BASED DA “ANNALS OF INTERNAL MEDICINE”

DISPEPSIA, GASTROENTEROLOGIA, IBS, MEDICI DI FAMIGLIA, MEDICINA INTERNA, NEWSLETTER, Senza categoria

Irritable Bowel Syndrome  Katarina B. Greer, MD, MS, and Shahnaz Sultan, MD, MHSc Irritable bowel syndrome (IBS) is a common gastrointestinal disorder, with a prevalence of 4% to 10%. It is a chronic condition characterized by abdominal pain in conjunction with altered bowel habits, abdominal distention, or bloating. IBS can present with 3 different defecation patterns: IBS with constipation, IBS…

CAMRELIZUMAB+ RIVOCERANIB PERIOPERATIVO VERSUS CHIRURGIA NEL CARCINOMA EPATOCELLULARE RESECABILE. L’EDITORIALE. DA” THE LANCET” (FREE)

CHIRURGIA, EPATOLOGIA, EPATOLOGIA ONCOLOGICA, GASTROENTEROLOGIA, NEWSLETTER, ONCOLOGIA

Perioperative camrelizumab plus rivoceranib versus surgery in resectable hepatocellular carcinoma Ahmed Kaseb ∙ Timothy M Pawlik Historically, hepatocellular carcinoma was deemed to be inherently drug resistant due to the presence of multidrug resistance genes that increased drug efflux and reduced drug uptake. For decades, multiple trials investigating systemic therapy for advanced hepatocellular carcinoma had failed to show clinical…

CAMRELIZUMAB + RIVOCERANIB PERIOPERATORIO MIGLIORA LA SOPRAVVIVENZA DEL CARCINOMA EPATOCELLULARE NEI PAZIENTI RESECABILI! UN TRIAL IMPORTANTE ! DA “THE LANCET” (FREE)

CHIRURGIA, EPATOLOGIA, EPATOLOGIA ONCOLOGICA, GASTROENTEROLOGIA, NEWSLETTER, ONCOLOGIA

Perioperative camrelizumab plus rivoceranib versus surgery alone in patients with resectable hepatocellular carcinoma at intermediate or high risk of recurrence (CARES – 009): a randomised phase 2/3 trial Prof Zheng Wang, et al. Summary Background Surgical resection is the preferred curative approach for patients with early-stage hepatocellular carcinoma, but recurrence remains a major challenge. Consequently,…